Synthesis of a Potent Bruton's Tyrosine Kinase Inhibitor Labelled With Carbon-14 and Deuterium

IF 0.9 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS
Bachir Latli, Magnus Eriksson
{"title":"Synthesis of a Potent Bruton's Tyrosine Kinase Inhibitor Labelled With Carbon-14 and Deuterium","authors":"Bachir Latli,&nbsp;Magnus Eriksson","doi":"10.1002/jlcr.4148","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Bruton's tyrosine kinase (BTK) is a cytoplasmic enzyme that plays a crucial role in B cell development, survival, proliferation and differentiation. This enzyme is expressed in several autoimmune diseases and cancers. Therefore, shutting out this enzyme with irreversible inhibitors is one of the strategies used to treat these diseases. The drug candidate <b>1</b> is a very potent and selective BTK inhibitor. Herein, we describe the preparation of this compound labelled with deuterium and carbon-14. Deuterium labelled <b>1</b> was prepared in 10 chemical steps and in 35% overall yield with more than 98% chemical purity and more than 99% isotopic enrichment. This synthesis was followed with the radioactive one as both synthetic routes were similar. Carbon-14 labelled <b>1</b> was prepared in eight radiochemical steps in 26% overall yield and in more than 99% radio and chemical purities and with specific activity of 53.1 mCi/mmol (1.96 GBq/mmol). This isotopically labelled compound was needed for DMPK and other studies.</p>\n </div>","PeriodicalId":16288,"journal":{"name":"Journal of labelled compounds & radiopharmaceuticals","volume":"68 5-6","pages":""},"PeriodicalIF":0.9000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of labelled compounds & radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jlcr.4148","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

Abstract

Bruton's tyrosine kinase (BTK) is a cytoplasmic enzyme that plays a crucial role in B cell development, survival, proliferation and differentiation. This enzyme is expressed in several autoimmune diseases and cancers. Therefore, shutting out this enzyme with irreversible inhibitors is one of the strategies used to treat these diseases. The drug candidate 1 is a very potent and selective BTK inhibitor. Herein, we describe the preparation of this compound labelled with deuterium and carbon-14. Deuterium labelled 1 was prepared in 10 chemical steps and in 35% overall yield with more than 98% chemical purity and more than 99% isotopic enrichment. This synthesis was followed with the radioactive one as both synthetic routes were similar. Carbon-14 labelled 1 was prepared in eight radiochemical steps in 26% overall yield and in more than 99% radio and chemical purities and with specific activity of 53.1 mCi/mmol (1.96 GBq/mmol). This isotopically labelled compound was needed for DMPK and other studies.

碳-14 -氘标记布鲁顿酪氨酸激酶抑制剂的合成
布鲁顿酪氨酸激酶(Bruton’s tyrosine kinase, BTK)是一种细胞质酶,在B细胞的发育、存活、增殖和分化过程中起着至关重要的作用。这种酶在几种自身免疫性疾病和癌症中表达。因此,用不可逆抑制剂关闭这种酶是治疗这些疾病的策略之一。候选药物1是一种非常有效的选择性BTK抑制剂。在这里,我们描述了用氘和碳-14标记的这种化合物的制备。标记为1的氘经过10个化学步骤,总产率为35%,化学纯度大于98%,同位素富集大于99%。由于这两种合成路线相似,因此随后又进行了放射性合成。碳-14标记1经8个放射化学步骤制备,总产率为26%,放射性和化学纯度超过99%,比活性为53.1 mCi/mmol (1.96 GBq/mmol)。这种同位素标记的化合物是DMPK和其他研究所需要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.30
自引率
0.00%
发文量
57
审稿时长
1 months
期刊介绍: The Journal of Labelled Compounds and Radiopharmaceuticals publishes all aspects of research dealing with labeled compound preparation and applications of these compounds. This includes tracer methods used in medical, pharmacological, biological, biochemical and chemical research in vitro and in vivo. The Journal of Labelled Compounds and Radiopharmaceuticals devotes particular attention to biomedical research, diagnostic and therapeutic applications of radiopharmaceuticals, covering all stages of development from basic metabolic research and technological development to preclinical and clinical studies based on physically and chemically well characterized molecular structures, coordination compounds and nano-particles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信